Skip to main content

Table 2 Association of NPAS2 rs6542993 with BCR in localized prostate cancer patients treated with RP

From: Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression

Gene SNP Genotype No. of patients No. of events 5-year survival rate (%) P a P b HR (95% CI) P c
NPAS2 rs6542993 AA 169 63 59.0    1.00  
   AT 229 90 58.8    1.40 (0.99–1.98) 0.059
   TT 57 29 41.6    2.34 (1.45–3.79) 0.001
   AT/TT vs AA     0.164 0.153 1.53 (1.10–2.14) 0.012
   TT vs AA/AT     0.034 0.028 1.92 (1.25–2.94) 0.003
   Trend     0.039 0.042 1.50 (1.18–1.91) 0.001
  1. PSA, prostate-specific antigen; RP, radical prostatectomy; SNP, single nucleotide polymorphism; HR, hazard ratio; 95% CI, 95% confidence interval
  2. P < 0.05 are in italicsface
  3. aP values were calculated using the log-rank test
  4. bP values were calculated after correcting for multiple tests by 1000 bootstrap resampling
  5. cHRs were adjusted for age, PSA at diagnosis, pathologic Gleason score, and pathologic stage